Loading…
Loading…
EQUITY / NASDAQ · XNGS
Indivior Pharmaceuticals, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗35.71 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 35.71 USD · Volume 1,669,289
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 343,000,000 USD | 302,000,000 USD | +13.58% |
| Operating profit | 160,000,000 USD | 72,000,000 USD | +122.22% |
| Net income | 122,000,000 USD | 18,000,000 USD | +577.78% |
| Cash and cash equivalents | 222,000,000 USD | — | — |
| Total liabilities | 1,441,000,000 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 222,000,000 USD | — | — | 195,000,000 USD | 195,000,000 USD | 445,000,000 USD | — | — |
| Gross profitIncome statement | 294,000,000 USD | 570,000,000 USD | — | — | 994,000,000 USD | 230,000,000 USD | 702,000,000 USD | 250,000,000 USD |
| Net incomeIncome statement | 122,000,000 USD | 211,000,000 USD | 89,000,000 USD | — | 210,000,000 USD | 42,000,000 USD | 108,000,000 USD | 18,000,000 USD |
| Operating profitIncome statement | 160,000,000 USD | 297,000,000 USD | — | — | 262,000,000 USD | 43,000,000 USD | 181,000,000 USD | 72,000,000 USD |
| RevenueIncome statement | 343,000,000 USD | 660,000,000 USD | — | — | 1,239,000,000 USD | 314,000,000 USD | 881,000,000 USD | 302,000,000 USD |
| Total assetsBalance sheet | 1,233,000,000 USD | — | — | 1,201,000,000 USD | 1,201,000,000 USD | 1,416,000,000 USD | — | — |
| Total equityBalance sheet | -208,000,000 USD | — | -144,000,000 USD | -98,000,000 USD | -98,000,000 USD | -207,000,000 USD | — | -257,000,000 USD |
| Total liabilitiesBalance sheet | 1,441,000,000 USD | — | — | 1,300,000,000 USD | 1,300,000,000 USD | 1,623,000,000 USD | — | — |
| Capital expendituresCash flow statement | — | 27,000,000 USD | — | — | 66,000,000 USD | — | 42,000,000 USD | — |
| Financing cash flowCash flow statement | — | -166,000,000 USD | — | — | -30,000,000 USD | — | -25,000,000 USD | — |
| Investing cash flowCash flow statement | — | -27,000,000 USD | — | — | -66,000,000 USD | — | -42,000,000 USD | — |
| Operating cash flowCash flow statement | — | 220,000,000 USD | — | — | -27,000,000 USD | — | 194,000,000 USD | — |
| Report source | Open report ↗ Published: 08/03/2026 | Open report ↗ Published: 08/03/2026 | Open report ↗ Published: 08/03/2026 | Open report ↗ Published: 08/03/2026 | Open report ↗ Published: 02/26/2026 | Open report ↗ Published: 10/30/2025 | Open report ↗ Published: 10/30/2025 | Open report ↗ Published: 08/03/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.